For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
Dear colleagues,
June marks both National Indigenous History Month and Pride Month. It is a time to learn about and honour the diverse cultures, histories, and experiences of First Nations, Inuit, and Métis Peoples, and to celebrate the strength, resilience, and contributions of 2SLGBTQI+ communities. It is also an opportunity to reflect on our shared responsibility to advance equitable, inclusive, and culturally safe clinical trial design and conduct.
CCTG is committed to fostering a research network that is safe, respectful, accessible, and inclusive. Our Equity, Diversity, Inclusivity, Indigenization, and Accessibility Policy recognizes that equity, respect for diversity, inclusion, Indigenization, and accessibility are essential to research excellence.
In 2025, CCTG established the Health Equity Committee whose work involves the integration of EDIIA principles and practices across our research, clinical trials, committees, and network activities. We are grateful to the more than 40 network members contributing to this important work, and to all of our network leaders and members for their continuing support of it.
Advancing reconciliation in clinical trials
CCTG recognizes that First Nations, Inuit, and Métis Peoples in Canada continue to experience inequities in cancer outcomes, including higher cancer incidence and mortality. As part of our commitment to the Truth and Reconciliation Commission of Canada’s Calls to Action, we are responding by addressing the harms of past research practices, building trust, and supporting culturally safe and inclusive clinical trials. The group is taking steps to strengthen reconciliation and decolonization education, build relationships with Indigenous partners, support culturally safe and co-designed research, and develop guidance for Indigenous clinical trial data governance.
Improving access to trials for 2SLGBTQI+ communities
2SLGBTQI+ people experience disparities in cancer outcomes compared with heterosexual and cisgender people and continue to face barriers to accessing cancer care and clinical trials. CCTG has taken steps to improve trial inclusivity by updating our generic protocol and informed consent templates, as well as patient-facing materials, to use more inclusive language. We also recognize the importance of considering both sex assigned at birth and gender identity in clinical trial design and analysis, and these variables are now considered in all CCTG-led trials.
CCTG remains committed to working with patient partners and organizations from 2SLGBTQI+ communities to further improve trial inclusivity and access.
ALC.10 (MM1OA-EA02), another myeloMATCH study, has opened in Canada comparing the usual treatment for FLT3 mutated acute myeloid leukemia (AML) with a new drug using two different treatment schedules to see if it improves outcomes for older patients. In this study the drug gilteritinib, a class of medications called kinase inhibitors, will be added to the current two drug treatment. It has different modes of action and acts as a differentiating agent for the bone marrow cells as well as helping to overcome resistance to venetoclax.
Final results from the CCTG HN.9 (EORTC 1740-HNCG) were presented at ASCO 2026, highlighting the challenges of reducing treatment intensity while maintaining outcomes for oropharyngeal cancer patients .
The results of the BR.31 global Phase III study, testing adjuvant durvalumab in patients with completely resected non–small cell lung cancer (NSCLC) were published in the Journal of Clinical Oncology.
Pausing endocrine treatment to attempt pregnancy can be considered - no additional risk of recurrences after 5 years. The MAC18 (POSITIVE) study, evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women
The Cancer Research Institute (CRI) and the Canadian Cancer Trials Group (CCTG) announced the enrollment of the first patient in the third sub study IND240C of their ongoing Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer (IPROC).
Results from the primary analysis of the ctDNA-negative cohort from the international DYNAMIC-III (CO.29) clinical trial were presented during the Presidential Symposium of the European Society for Medical Oncology Congress in Berlin
No Chemotherapy in Intermediate-risk HR + HER2- Early Breast Cancer Treated with Ribociclib (NoLEEta)
Combination Therapy with Luspatercept in Lower Risk Myelodysplasia: A Tier 1 myeloMATCH Substudy
Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3)
NeoAdjuvant-only or Peri-operative cemiplimab in high-grade localised soft-tissue SARcoma (NAPStAR)
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
Using SMART to optimize the stepped care delivery of TEMPO – a Tailored, dyadic, wEb-based physical activity and self-Management PrOgram for men with prostate cancer and their caregivers (TEMPO)
Feasibility, Acceptability and Representativeness: Collecting Sociodemographic Data in CCTG Trials
One of the world’s largest randomized clinical trials, investigating the use of fecal microbiota transplantation (FMT) has opened in Canada.
MAC30 has recently opened in Canada and will compare two commonly used treatment choices for premenopausal women with ER-positive/HER2-negative breast cancer and a low to intermediate risk of recurrence.
A new CCTG national study has received funding from the Social Sciences and Humanities Research Council and Genome Canada to explore the ethical questions raised with emerging cancer technologies like CAR-T cell therapy.
